Matt Salo, executive director of the National Association of Medicaid Directors, is emerging as one of the most important observers in how the expansion of the leading healthcare program for poor Americans is unfolding across the country. In December's issue of The American Journal of Accountable Care, he addresses how the fallout of the 2014 midterms will affect Medicaid in the near term.
AJAC Features Matt Salo on Medicaid After the Midterms
FOR IMMEDIATE RELEASEDecember 30, 2014
Will Medicaid expansion continue in the face of Republican gains in both houses of Congress and in statehouses nationwide, even in places like Massachusetts and Maryland? If so, what will expansion look like? And what of the “super waivers” permitted by the Affordable Care Act (ACA) in 2017, after President Obama leaves office?
How states put their individual stamps on Medicaid and the ACA is the business of Matt Salo, the executive director of the National Association of Medicaid Directors, who writes in this month’s issue of The American Journal of Accountable Care on “The 2014 Elections and the Future of Medicaid.” For the full article, click here.
Mr Salo makes a number of key observations about Medicaid expansion, with perhaps the most important being that as Republican-led states craft their own plans, leaders should not assume any waiver concept will be rejected, based on approvals in Iowa, Pennsylvania, and Michigan. “In fact, the approval of the expansion in those states demonstrated an evolution of the administration's original thinking on the expansion, creating in effect, an iterative process where you don't know what can be approved until you ask,” he writes.
After Mr Salo’s article went to press, Medicaid expansion plans or possibilities were announced in Tennessee, Alabama, Florida, and Utah, including some with work requirements that were previously rejected in Pennsylvania.
Also of importance, as 2016 presidential candidates emerge, is the concept of the “super waiver,” which Mr Salo notes almost no one has mentioned. Permitted after 2017 by the ACA, these waivers would allow entire portions of the ACA to be set aside as long as the law’s broad concepts are left intact.
About the Journals
The American Journal of Managed Care, now in its 20th year of publication, is the leading peer-reviewed journal dedicated to issues in managed care. The American Journal of Pharmacy Benefits, provides pharmacy and formulary decision-makers with information to improve the efficiency and health outcomes in managing pharmaceutical care. In December 2013, AJMC introduced The American Journal of Accountable Care, which publishes research and commentary devoted to understanding changes to the healthcare system due to the 2010 Affordable Care Act. AJMC’s news publications, the Evidence-Based series, bring together stakeholder views from payers, providers, policymakers and pharmaceutical leaders in oncology and diabetes management. To order reprints of articles appearing in AJMC publications, please call (609) 716-7777, x 131.
CONTACT: Mary Caffrey (609) 716-7777 x 144
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
An Overview of Health Care and Pharmaceutical Trends, 2023-2024
April 19th 2024Douglas M. Long, BA, MBA, was featured as the keynote speaker on the closing day of The Academy of Managed Care Pharmacy 2024 annual meeting, with a session dedicated to surveying the health care and pharmaceutical trends of the last year.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More